In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent ...

(RTTNews) - Shares of Emergent BioSolutions (EBS) are down 12.74% in premarket trading Tuesday following the company's financial results for the fourth quarter and full year ended December 31, 2024.

Emergent Biosolutions (EBS) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to loss of $0.77 per share a year ago.